Sydnexis Receives Positive CHMP Opinion for SYD-101 in Pediatric Myopia Sydnexis, Inc., a pre-commercial biopharmaceutical company, has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Tris Pharma to Present Data on Cebranopadol at AAPM PainConnect Meeting Tris Pharma, Inc., a biopharmaceutical company focused on commercial-stage development, has announced its participation in the upcoming 2025 American…
Corcept’s Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer Meets Primary Endpoint Corcept Therapeutics Incorporated (NASDAQ: CORT), a company focused on developing treatments for serious endocrinologic, oncologic, metabolic,…
ABEC Launches Breakthrough Single-Use Bioreactor Technology for Cell Therapy ABEC, a global leader in engineered solutions and services for biotech manufacturing, has unveiled its Advanced Therapy Bioreactor (ATB™), a groundbreaking…
Enigma Biomedical Partners to Use 4R PET Imaging Biomarkers in CTE Research Enigma Biomedical USA, Inc. (EB USA) has announced an exciting new collaboration with the Boston University Chronic Traumatic…
GE HealthCare Acquires Nihon Medi-Physics, Leading Radiopharmaceutical Company in Japan GE HealthCare Technologies Inc. (Nasdaq: GEHC) has successfully completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co.,…
Novotech Secures New Investment from GIC, Temasek, and TPG to Boost Global Growth Novotech, a leading full-service biotech clinical research organization (CRO), announced today that affiliates of GIC and Temasek…
ACC 2025: Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively Sensydia, a clinical-stage company focused on non-invasive cardiac assessments, recently showcased promising clinical findings from a study on its…
Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Forms Altasciences, a recognized leader in contract development and manufacturing (CDMO) services, has been honored with the 2025 CDMO Leadership…
CRISPR Cas9 Market Set for Exponential Growth with Gene Therapy Advancements The latest “CRISPR Cas9 Market” report has been added to ResearchAndMarkets.com’s offerings, highlighting the transformative potential of CRISPR/Cas9 technology…
Bristol Myers Squibb’s Opdivo-Based Perioperative Regimen Receives Positive CHMP Opinion for Resectable NSCLC Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP)…
Curatis Achieves 30% Sales Growth & Expands C-PTBE-01 Patient Reach Curatis Holding AG (SIX:CURN, ‘Curatis’) has reported strong business performance in 2024, achieving business revenues of CHF 6.9 million, with…